InnoCan Pharma (INNO) Price & Analysis

Compare

22 Followers

INNO Stock Chart & Stats

C$7.50

C$0.01(5.26%)

At close: Jan 08 4:00 PM EST

C$7.50

C$0.01(5.26%)

Day’s Range― - ―

52-Week RangeC$6.01 - C$21.00

Previous CloseN/A

Volume118.77K

Average Volume (3M)920.00

Market Cap

C$40.49M

Enterprise ValueC$15.37M

Total Cash (Recent Filing)C$10.22M

Total Debt (Recent Filing)C$2.12M

Price to Earnings (P/E)―

Beta-0.54

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding4,498,772

10 Day Avg. Volume392

30 Day Avg. Volume920

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)7.71

Price to Sales (P/S)1.35

P/FCF Ratio-25.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginAn 88.45% gross margin is a durable structural advantage: it indicates strong unit economics or premium product pricing that can absorb SG&A and R&D without immediate margin collapse, supporting sustained investment in development and commercialization over months.

Proprietary Delivery TechnologyOwnership of proprietary cannabinoid delivery platforms creates a meaningful competitive moat: differentiated formulations and controlled-release tech can support higher pricing, licensing, and partnerships, and form the basis of lasting revenue streams beyond commodity product sales.

Low LeverageA low debt-to-equity ratio provides financial flexibility and lowers default risk, enabling the company to fund trials, commercialization, or strategic partnerships without onerous interest burdens. This balance-sheet strength supports resilience over the next several quarters.

Bears Say

Negative ProfitabilitySustained negative profitability and negative operating margins indicate the business is not yet self-sustaining; this limits retained earnings for reinvestment and requires either rapid operating improvement or external capital to fund growth and translate gross-margin strength into net profits.

Weak Cash GenerationSeverely deteriorated free cash flow growth and negative operating cash conversion reduce runway and increase reliance on financing. Over a multi-month horizon this constrains R&D, commercialization budgets, and strategic flexibility, raising dilution and execution risk.

Limited Revenue GrowthModest top-line growth limits the company's ability to scale fixed costs and leverage high gross margins into sustainable operating profits. Without stronger revenue expansion, margin improvement and return on R&D investments may remain constrained over the next several quarters.

InnoCan Pharma News

Innocan Pharma Targets NYSE American Listing With Concurrent Offering

The latest announcement is out from InnoCan Pharma ( ($TSE:INNO) ). Innocan Pharma Corporation plans to list its...

8d ago

Innocan Pharma Targets NYSE American Listing with Concurrent Securities Offering

InnoCan Pharma ( ($TSE:INNO) ) has shared an update. Innocan Pharma Corporation plans to list its common shares...

1M ago

Innocan Pharma Unveils Promising Advances in CBD Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma announced promising preliminary findings regarding its liposomal...

2M ago

Innocan Pharma Files Amended Registration for U.S. Public Offering

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma has announced the public filing of an...

2M ago

Innocan Pharma Reports 2025 Financial Results

Innocan Pharma Corporation ( ($INNPF) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

Innocan Pharma Reports Q3 2025 Results and Advances Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma reported its Q3 2025 financial results, showing...

2M ago

Innocan Pharma’s LPT-CBD Shows Promising Results in Pain Relief Study

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma has published promising results from a study...

2M ago

Innocan Pharma to Showcase Innovative Pain Management Platform at 2025 ThinkEquity Conference

An announcement from InnoCan Pharma ( ($TSE:INNO) ) is now available. Innocan Pharma announced its participation in the...

3M ago

Innocan Pharma Secures Patent for LPT-CBD in Japan, Strengthening Global IP Portfolio

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma announced that its patent for the Liposomal...

4M ago

Innocan Pharma’s LPT-CBD Injections Transform Animal Care at Freedom Farm

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma has partnered with Freedom Farm to provide...

5M ago

INNO FAQ

What was InnoCan Pharma’s price range in the past 12 months?

InnoCan Pharma lowest stock price was C$6.01 and its highest was C$21.00 in the past 12 months.

What is InnoCan Pharma’s market cap?

InnoCan Pharma’s market cap is C$40.49M.

When is InnoCan Pharma’s upcoming earnings report date?

InnoCan Pharma’s upcoming earnings report date is Mar 26, 2026 which is in 49 days.

How were InnoCan Pharma’s earnings last quarter?

InnoCan Pharma released its earnings results on Nov 26, 2025. The company reported -C$0.596 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.596.

Is InnoCan Pharma overvalued?

According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InnoCan Pharma pay dividends?

InnoCan Pharma does not currently pay dividends.

What is InnoCan Pharma’s EPS estimate?

InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InnoCan Pharma have?

InnoCan Pharma has 4,498,772 shares outstanding.

What happened to InnoCan Pharma’s price movement after its last earnings report?

InnoCan Pharma reported an EPS of -C$0.596 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of InnoCan Pharma?

Currently, no hedge funds are holding shares in TSE:INNO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InnoCan Pharma

InnoCan Pharma (INNO) is a biotechnology company focused on developing innovative therapeutic solutions leveraging cannabinoid-based technologies. The company operates primarily in the pharmaceutical and wellness sectors, with a core emphasis on creating advanced treatments for various medical conditions, including dermatological ailments and neurological disorders. InnoCan Pharma is known for its proprietary delivery systems that enhance the bioavailability of cannabinoids, aiming to revolutionize how these compounds are utilized in medical applications.